UK Markets closed

2 Hot Biotech IPOs to Consider

·4-min read
2 Hot Biotech IPOs to Consider
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Especially for companies that are expected to be growing right out of the gate, getting in during the market's initial feeding frenzy sometimes means buying a stock when it's as cheap as it will ever be. In this vein, Recursion Pharmaceuticals (NASDAQ: RXRX) and Biomea Fusion (NASDAQ: BMEA) are a pair of biotechs that had their IPOs last week, and both have unique value for investors that could make them worth a (speculative) buy. Recursion's information technology-heavy approach to drug discovery could make it a rising star on the basis of its already extensive list of development collaborations alone.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting